BioCentury | Oct 9, 2020
Translation in Brief

Philogen immunocytokine for glioma; plus Nordic's radiotherapy, Beth Israel Deaconness, Molecular Partners and Alpine

...modelling acute myeloid leukemia that had been given human peripheral blood mononuclear cells. The dual, inducible ICOS/CD28...
...Inc. Nordic Nanovector ASA Molecular Partners AG Inducible T cell co-stimulator ligand (ICOSLG) (B7-H2) (B7RP1) CD28 Inducible T cell co-stimulator (ICOS) CC...
BioCentury | Sep 1, 2020
Deals

Gilead deal clears path for Jounce to advance immuno-oncology programs

...near-term expenditures are associated with its lead program, anti-ICOS...
...second-line NSCLC patients.Some doubts had arisen about ICOS’s...
BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

...exclusive, worldwide option to license ALPN-101, an Fc fusion protein dual antagonist of CD28 and ICOS...
...Remy Durand, Alpine’s SVP of BD and corporate strategy, told BioCentury that ALPN-101’s dual CD28/ICOS...
...a key co-stimulatory receptor on naïve T cells. Once differentiated into effector T cells, however, ICOS...
BioCentury | Jun 13, 2020
Product Development

Where companies see opportunity in the crowded PD-1 marketplace

...no approved PD-1 inhibitors. An example of the first arm of the strategy is GSK’s ICOS...
...Epidermal growth factor receptor HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 ICOS...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...also make an appearance at the meeting. GSK will present an updated analysis of its ICOS...
...Epidermal growth factor receptor 2 HER3 (ERBB3; EGFR3) - Erb-b2 receptor tyrosine kinase 3 ICOS...
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

...but was able to reintroduce it to patients at a lower dose. The immunostimulatory receptor ICOS...
BioCentury | May 15, 2020
Product Development

TIGIT emerges as a standout next generation checkpoint target at ASCO

...BioCentury. Other checkpoint targets that haven’t fared as well in the clinic include 4-1BB and ICOS...
...concerns across trials over the past five years, and investors have questioned the potential of ICOS...
...factor receptor superfamily member 9 HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 ICOS...
BioCentury | Oct 19, 2019
Product Development

How GSK has rebuilt its oncology pipeline from the ground up

...advanced next-generation checkpoint therapy, an ICOS agonist antibody. At ESMO last month, GSK reported its ICOS...
...against ICOS in the clinic, including Jounce Therapeutics Inc. Jounce reported modest data for its ICOS...
...the INDUCE-1 study were at this point independent of ICOS status." Hoos told BioCentury while ICOS...
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

...in 2015. ICOS has two that have reached Phase II. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has anti-ICOS...
...Cytotoxic T-lymphocyte associated protein 4 GITR (TNFRSF18) - Glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein ICOS...
...1 (CEACAM1) (CD66a) CD80 (B7-1) Glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR) (TNFRSF18) Inducible T cell co-stimulator (ICOS) Lymphocyte-activation...
BioCentury | Oct 3, 2019
Emerging Company Profile

X-Vax: Bucking dogma in HSV vaccine development

...covering the vaccine from Albert Einstein College of Medicine. Blech co-founded Celgene Corp. (NASDAQ:CELG) and ICOS Corp....
Items per page:
1 - 10 of 623
BioCentury | Oct 9, 2020
Translation in Brief

Philogen immunocytokine for glioma; plus Nordic's radiotherapy, Beth Israel Deaconness, Molecular Partners and Alpine

...modelling acute myeloid leukemia that had been given human peripheral blood mononuclear cells. The dual, inducible ICOS/CD28...
...Inc. Nordic Nanovector ASA Molecular Partners AG Inducible T cell co-stimulator ligand (ICOSLG) (B7-H2) (B7RP1) CD28 Inducible T cell co-stimulator (ICOS) CC...
BioCentury | Sep 1, 2020
Deals

Gilead deal clears path for Jounce to advance immuno-oncology programs

...near-term expenditures are associated with its lead program, anti-ICOS...
...second-line NSCLC patients.Some doubts had arisen about ICOS’s...
BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

...exclusive, worldwide option to license ALPN-101, an Fc fusion protein dual antagonist of CD28 and ICOS...
...Remy Durand, Alpine’s SVP of BD and corporate strategy, told BioCentury that ALPN-101’s dual CD28/ICOS...
...a key co-stimulatory receptor on naïve T cells. Once differentiated into effector T cells, however, ICOS...
BioCentury | Jun 13, 2020
Product Development

Where companies see opportunity in the crowded PD-1 marketplace

...no approved PD-1 inhibitors. An example of the first arm of the strategy is GSK’s ICOS...
...Epidermal growth factor receptor HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 ICOS...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...also make an appearance at the meeting. GSK will present an updated analysis of its ICOS...
...Epidermal growth factor receptor 2 HER3 (ERBB3; EGFR3) - Erb-b2 receptor tyrosine kinase 3 ICOS...
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

...but was able to reintroduce it to patients at a lower dose. The immunostimulatory receptor ICOS...
BioCentury | May 15, 2020
Product Development

TIGIT emerges as a standout next generation checkpoint target at ASCO

...BioCentury. Other checkpoint targets that haven’t fared as well in the clinic include 4-1BB and ICOS...
...concerns across trials over the past five years, and investors have questioned the potential of ICOS...
...factor receptor superfamily member 9 HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 ICOS...
BioCentury | Oct 19, 2019
Product Development

How GSK has rebuilt its oncology pipeline from the ground up

...advanced next-generation checkpoint therapy, an ICOS agonist antibody. At ESMO last month, GSK reported its ICOS...
...against ICOS in the clinic, including Jounce Therapeutics Inc. Jounce reported modest data for its ICOS...
...the INDUCE-1 study were at this point independent of ICOS status." Hoos told BioCentury while ICOS...
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

...in 2015. ICOS has two that have reached Phase II. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has anti-ICOS...
...Cytotoxic T-lymphocyte associated protein 4 GITR (TNFRSF18) - Glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein ICOS...
...1 (CEACAM1) (CD66a) CD80 (B7-1) Glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR) (TNFRSF18) Inducible T cell co-stimulator (ICOS) Lymphocyte-activation...
BioCentury | Oct 3, 2019
Emerging Company Profile

X-Vax: Bucking dogma in HSV vaccine development

...covering the vaccine from Albert Einstein College of Medicine. Blech co-founded Celgene Corp. (NASDAQ:CELG) and ICOS Corp....
Items per page:
1 - 10 of 623